577:(EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Tecvayli, intended for treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies. Tecvayli was reviewed under EMA's accelerated assessment program. The applicant for this medicinal product is Janssen-Cilag International N.V. Teclistamab was approved for medical use in the European Union in August 2022.
3784:
1177:
1130:
947:
540:
Teclistamab-cqyv was evaluated in MajesTEC-1 (NCT03145181; NCT04557098), a single-arm, multi-cohort, open-label, multi-center study. The efficacy population consisted of 110 participants who had previously received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory
531:
The most common adverse reactions (≥20%) occurring in the 165 patients in the safety population, were pyrexia, CRS, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea. The most common Grade 3 to 4 laboratory
1032:
972:
883:
737:
523:(ICANS). Among people who received teclistamab at the recommended dose, CRS occurred in 72%, neurologic toxicity in 57%, and ICANS in 6%. Grade 3 CRS occurred in 0.6% of people and Grade 3 or 4 neurologic toxicity occurred in 2.4%.
964:
482:
Teclistamab is the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. Teclistamab was approved for medical use in the
European Union in August 2022, and in the United States in October 2022. The US
875:
1115:
1024:
932:
1366:
216:
727:
965:"Janssen Marks First Approval Worldwide for Tecvayli (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma"
673:
171:
1002:
876:"Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody Tecvayli (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)"
1103:
770:
1025:"U.S. FDA Approves Tecvayli (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma"
2797:
1359:
924:
570:
800:
1352:
3804:
36:
1294:
3206:
532:
abnormalities (≥20%) were decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets.
2358:
2001:
862:
Text was copied from this source which is copyright
European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
3738:
3407:
3627:
2790:
1494:
849:
665:
3264:
3191:
3096:
2472:
994:
3121:
586:
1892:
1418:
762:
3809:
2783:
201:
89:
614:
3106:
705:
417:
1245:
Martino EA, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M (October 2023).
1196:"Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody"
3211:
3774:
3070:
2238:
1156:
1109:
998:
928:
796:
484:
451:(low immunoglobulin or antibody levels in the blood, which increases the risk of infection), cytokine release syndrome,
307:
1162:
108:
3755:
1395:
2419:
2849:
2544:
2393:
2142:
1644:
41:
3314:
1869:
1735:
1448:
1316:
792:
574:
516:
488:
437:
65:
1879:
1405:
3743:
3710:
3651:
3602:
3517:
3141:
1375:
1319:(2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82".
464:
145:
3681:
3671:
3641:
3432:
3377:
3304:
3294:
3171:
2247:
1730:
1459:
1286:
152:
637:"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)"
3814:
3656:
3645:
3607:
3497:
3482:
3412:
3392:
3387:
3166:
2920:
1805:
1745:
1715:
1618:
1454:
1344:
448:
3507:
3367:
3136:
3101:
1660:
1555:
1392:
636:
553:
3622:
3592:
3587:
3572:
3402:
3249:
3201:
3161:
2806:
2513:
1780:
1770:
1590:
267:
48:
29:
2860:
3344:
2895:
2855:
2168:
1810:
1800:
1785:
1705:
119:
479:(infection of the lungs), nausea (feeling sick), fever, headache, cough, constipation and pain.
541:
agent, and an anti-CD38 monoclonal antibody, and had not received prior BCMA-targeted therapy.
3231:
3050:
1845:
1268:
1227:
1085:
228:
841:
276:
1685:
1527:
1522:
1328:
1258:
1217:
1207:
1075:
1067:
460:
425:
421:
352:
69:
316:
3788:
549:
459:(low levels of red blood cells or hemoglobin), pain in the muscles and bones, tiredness,
1222:
1195:
3749:
3715:
3382:
2622:
2520:
2468:
2066:
1379:
1080:
1055:
164:
3798:
3597:
3452:
3005:
2840:
2679:
2569:
2531:
2508:
2440:
2435:
2425:
2201:
2197:
2185:
1992:
1775:
1740:
1560:
1540:
1181:
1134:
951:
732:
728:"Notice: Multiple additions to the Prescription Drug List (PDL) [2023-10-26]"
700:
520:
512:
240:
3612:
3577:
3562:
3557:
3552:
3547:
3522:
3477:
3472:
3467:
3462:
3447:
3334:
3309:
3289:
3151:
3116:
3055:
3035:
2845:
2830:
2775:
2719:
2704:
2674:
2654:
2536:
2484:
2445:
2333:
2312:
2219:
2181:
2082:
2057:
2053:
1937:
1902:
1855:
1840:
1795:
1670:
1640:
1565:
1383:
606:
184:
179:
695:
3720:
3694:
3689:
3661:
3637:
3632:
3567:
3542:
3532:
3502:
3492:
3457:
3442:
3427:
3417:
3397:
3372:
3357:
3329:
3279:
3274:
3269:
3254:
3244:
3221:
3216:
3186:
3131:
3075:
3065:
3040:
3030:
3025:
3020:
2995:
2970:
2960:
2955:
2950:
2940:
2925:
2910:
2905:
2890:
2885:
2875:
2870:
2865:
2835:
2749:
2729:
2724:
2714:
2694:
2669:
2664:
2647:
2595:
2585:
2580:
2575:
2477:
2404:
2374:
2369:
2364:
2348:
2338:
2318:
2193:
2189:
2177:
2173:
2102:
2006:
1952:
1947:
1912:
1850:
1825:
1820:
1815:
1790:
1755:
1710:
1690:
1680:
1635:
1600:
1580:
1536:
1499:
1487:
1482:
1444:
1428:
545:
468:
452:
1071:
455:(low levels of neutrophils, a type of white blood cell that fights infection),
3666:
3617:
3582:
3512:
3487:
3437:
3422:
3362:
3352:
3324:
3299:
3239:
3181:
3176:
3111:
3091:
3045:
3015:
3010:
3000:
2990:
2985:
2975:
2965:
2935:
2930:
2900:
2880:
2764:
2759:
2734:
2699:
2684:
2659:
2642:
2632:
2590:
2561:
2526:
2492:
2409:
2399:
2379:
2343:
2328:
2323:
2293:
2227:
2223:
2205:
2153:
2132:
2092:
2087:
2026:
1957:
1932:
1907:
1830:
1765:
1725:
1720:
1700:
1695:
1675:
1665:
1655:
1570:
1550:
1532:
1440:
391:
159:
3537:
3527:
3319:
3284:
3259:
3196:
3156:
3146:
3126:
3060:
2980:
2945:
2915:
2754:
2744:
2739:
2709:
2689:
2637:
2627:
2615:
2610:
2556:
2551:
2497:
2430:
2303:
2298:
2283:
2278:
2273:
2263:
2258:
2253:
2158:
2148:
2127:
2122:
2117:
2112:
2107:
2097:
2077:
2041:
2036:
2031:
2021:
2016:
1983:
1978:
1973:
1942:
1922:
1917:
1760:
1750:
1575:
1423:
1147:
500:
476:
441:
53:
22:
1272:
1231:
1089:
925:"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma"
503:
for the treatment of adults with relapsed and refractory multiple myeloma.
2815:
2504:
2268:
2072:
2011:
1967:
1927:
1897:
1650:
1514:
1510:
1435:
1212:
519:(CRS) and neurologic toxicity, including immune effector cell-associated
472:
463:(low levels of blood platelets, components that help the blood to clot),
287:
103:
1333:
296:
1608:
60:
1263:
1246:
1104:"Advancing Health Through Innovation: New Drug Therapy Approvals 2022"
456:
433:
429:
336:
2488:
2214:
2048:
1997:
1477:
1180:
This article incorporates text from this source, which is in the
1133:
This article incorporates text from this source, which is in the
950:
This article incorporates text from this source, which is in the
2603:
2389:
1887:
1613:
1595:
1585:
1545:
1413:
327:
249:
2779:
1348:
234:
98:
644:
511:
In the US, the prescribing information for teclistamab has a
210:
130:
471:(low levels of lymphocytes, a type of white blood cell),
223:
467:, upper respiratory tract (nose and throat) infection,
3772:
870:
868:
757:
755:
3703:
3680:
3343:
3230:
3084:
2823:
2814:
2460:
2237:
1878:
1868:
1628:
1509:
1469:
1404:
1391:
390:
351:
346:
326:
306:
286:
266:
261:
200:
195:
170:
158:
144:
118:
88:
80:
75:
59:
47:
35:
28:
919:
917:
915:
913:
911:
909:
907:
905:
903:
901:
420:used for the treatment of relapsed and refractory
836:
834:
832:
830:
828:
826:
824:
822:
820:
818:
424:. It is a bispecific antibody that targets the
275:
571:Committee for Medicinal Products for Human Use
2791:
1360:
8:
544:The application for teclistamab was granted
107:
21:
2820:
2798:
2784:
2776:
1875:
1401:
1367:
1353:
1345:
1332:
1262:
1221:
1211:
1079:
315:
440:), which is expressed on the surface of
3779:
598:
295:
1247:"Teclistamab-cqyv in multiple myeloma"
670:Therapeutic Goods Administration (TGA)
611:Therapeutic Goods Administration (TGA)
20:
852:from the original on 10 December 2022
773:from the original on 18 November 2022
676:from the original on 19 November 2023
617:from the original on 19 November 2023
447:The most common side effects include
428:receptor expressed on the surface of
7:
1291:Union Register of medicinal products
1165:from the original on 14 January 2024
1118:from the original on 21 January 2023
1005:from the original on 27 October 2022
975:from the original on 26 October 2022
935:from the original on 27 October 2022
803:from the original on 4 December 2022
183:
740:from the original on 3 January 2024
335:
1035:from the original on 10 March 2024
666:"Tecvayli (Janssen-Cilag Pty Ltd)"
444:multiple myeloma B-lineage cells.
14:
1297:from the original on 3 March 2023
971:(Press release). 24 August 2022.
886:from the original on 30 July 2022
793:"Drug Approval Package: Tecvayli"
763:"Tecvayli- teclistamab injection"
708:from the original on 3 March 2024
587:international nonproprietary name
3805:Monoclonal antibodies for tumors
3782:
1175:
1128:
1029:Janssen Pharmaceutical Companies
969:Janssen Pharmaceutical Companies
945:
369:
363:
1251:European Journal of Haematology
1148:New Drug Therapy Approvals 2022
882:(Press release). 22 July 2022.
589:and owned by Genmab A/S (INN).
1287:"Tecvayli Product information"
1200:Cancer Management and Research
995:"Tecvayli: FDA-Approved Drugs"
515:for life threatening or fatal
418:bispecific monoclonal antibody
381:
375:
357:
84:JNJ-64007957, teclistamab-cqyv
1:
1056:"Teclistamab: First Approval"
1157:Food and Drug Administration
1110:Food and Drug Administration
999:Food and Drug Administration
929:Food and Drug Administration
797:Food and Drug Administration
485:Food and Drug Administration
412:, sold under the brand name
487:(FDA) considers it to be a
3831:
1870:Tyrosine kinase inhibitors
1072:10.1007/s40265-022-01793-1
347:Chemical and physical data
42:Bi-specific T-cell engager
3733:
3315:Mirvetuximab soravtansine
1736:Mirvetuximab soravtansine
1317:World Health Organization
1194:Pan D, Richter J (2023).
846:European Medicines Agency
799:(FDA). 23 November 2022.
575:European Medicines Agency
517:cytokine release syndrome
489:first-in-class medication
1880:Receptor tyrosine kinase
1406:Receptor tyrosine kinase
1161:(Report). January 2024.
1054:Kang C (November 2022).
931:(FDA). 25 October 2022.
465:injection site reactions
3711:Depatuxizumab mafodotin
3652:Tucotuzumab celmoleukin
3603:Rovalpituzumab tesirine
3518:Lorvotuzumab mertansine
3408:Clivatuzumab tetraxetan
1470:Others for solid tumors
1376:Targeted cancer therapy
696:"Details for: Tecvayli"
3810:Immunomodulating drugs
3672:Vorsetuzumab mafodotin
3628:Tacatuzumab tetraxetan
3433:Denintuzumab mafodotin
3378:Bivatuzumab mertansine
3305:Loncastuximab tesirine
3295:Indatuximab ravtansine
3172:Naptumomab estafenatox
1731:Loncastuximab tesirine
1460:Trastuzumab deruxtecan
153:Subcutaneous injection
3657:Vandortuzumab vedotin
3608:Sacituzumab govitecan
3498:Inotuzumab ozogamicin
3483:Gemtuzumab ozogamicin
3413:Cofetuzumab pelidotin
3393:Cantuzumab ravtansine
3388:Cantuzumab mertansine
3207:Nofetumomab merpentan
3167:Moxetumomab pasudotox
2921:Glembatumumab vedotin
2807:Monoclonal antibodies
1806:Sacituzumab govitecan
1746:Moxetumomab pasudotox
1716:Inotuzumab ozogamicin
1619:Gemtuzumab ozogamicin
1455:Trastuzumab emtansine
1396:monoclonal antibodies
1380:antineoplastic agents
569:On 21 July 2022, the
449:hypogammaglobulinemia
3704:Chimeric + humanized
3508:Lifastuzumab vedotin
3368:Belantamab mafodotin
3137:Ibritumomab tiuxetan
3102:Anatumomab mafenatox
1661:Belantamab mafodotin
1321:WHO Drug Information
1293:. 12 December 2022.
1213:10.2147/CMAR.S372237
554:breakthrough therapy
436:maturation antigen (
3623:Sofituzumab vedotin
3593:Polatuzumab vedotin
3588:Pinatuzumab vedotin
3573:Oportuzumab monatox
3403:Citatuzumab bogatox
3265:Derlotuximab biotin
3250:Brentuximab vedotin
3202:Taplitumomab paptox
3192:Satumomab pendetide
3162:Nacolomab tafenatox
3097:Altumomab pentetate
2514:Denileukin diftitox
2176:(ALK, ROS1, NTRK),
1781:Polatuzumab vedotin
1771:Oportuzumab monatox
1114:. 10 January 2023.
1031:. 25 October 2022.
769:. 31 October 2022.
736:. 26 October 2023.
704:. 20 October 2023.
585:Teclistamab is the
560:Society and culture
219:(Prescription only)
30:Monoclonal antibody
25:
16:Monoclonal antibody
3760:Never to phase III
3122:Capromab pendetide
2896:Enfortumab vedotin
2200:(ROS1, TRK, ALK),
1706:Enfortumab vedotin
3770:
3769:
3729:
3728:
3051:Tisotumab vedotin
2773:
2772:
2456:
2455:
1864:
1863:
1846:Tisotumab vedotin
1264:10.1111/ejh.14121
1066:(16): 1613–1619.
507:Contraindications
407:
406:
253:
238:
226:
214:
134:
101:
3822:
3787:
3786:
3785:
3778:
3682:Rat/mouse hybrid
2821:
2800:
2793:
2786:
2777:
2487:peptide against
2060:(AXL, ALK, LTK))
1876:
1686:Dinutuximab beta
1402:
1369:
1362:
1355:
1346:
1339:
1338:
1336:
1313:
1307:
1306:
1304:
1302:
1283:
1277:
1276:
1266:
1242:
1236:
1235:
1225:
1215:
1191:
1185:
1179:
1178:
1174:
1172:
1170:
1152:
1144:
1138:
1132:
1131:
1127:
1125:
1123:
1100:
1094:
1093:
1083:
1051:
1045:
1044:
1042:
1040:
1021:
1015:
1014:
1012:
1010:
991:
985:
984:
982:
980:
961:
955:
949:
948:
944:
942:
940:
921:
896:
895:
893:
891:
872:
863:
861:
859:
857:
848:. 18 July 2022.
838:
813:
812:
810:
808:
789:
783:
782:
780:
778:
759:
750:
749:
747:
745:
724:
718:
717:
715:
713:
692:
686:
685:
683:
681:
672:. 28 July 2023.
662:
656:
655:
653:
651:
641:nctr-crs.fda.gov
633:
627:
626:
624:
622:
613:. 28 June 2023.
603:
461:thrombocytopenia
422:multiple myeloma
402:
400:
383:
377:
371:
365:
359:
339:
319:
299:
279:
251:
248:
243:
236:
233:
225:
222:
212:
209:
187:
132:
129:
111:
100:
97:
26:
24:
3830:
3829:
3825:
3824:
3823:
3821:
3820:
3819:
3795:
3794:
3793:
3783:
3781:
3773:
3771:
3766:
3765:
3750:Clinical trials
3725:
3699:
3676:
3339:
3226:
3080:
2810:
2804:
2774:
2769:
2623:Pi3K inhibitors
2521:mTOR inhibitors
2452:
2233:
2204:(VEGFR, FGFR),
1860:
1624:
1505:
1465:
1387:
1373:
1343:
1342:
1315:
1314:
1310:
1300:
1298:
1285:
1284:
1280:
1244:
1243:
1239:
1193:
1192:
1188:
1176:
1168:
1166:
1150:
1146:
1145:
1141:
1129:
1121:
1119:
1102:
1101:
1097:
1053:
1052:
1048:
1038:
1036:
1023:
1022:
1018:
1008:
1006:
993:
992:
988:
978:
976:
963:
962:
958:
946:
938:
936:
923:
922:
899:
889:
887:
874:
873:
866:
855:
853:
842:"Tecvayli EPAR"
840:
839:
816:
806:
804:
791:
790:
786:
776:
774:
761:
760:
753:
743:
741:
726:
725:
721:
711:
709:
694:
693:
689:
679:
677:
664:
663:
659:
649:
647:
635:
634:
630:
620:
618:
605:
604:
600:
595:
583:
567:
562:
550:priority review
538:
529:
527:Adverse effects
509:
499:Teclistamab is
497:
398:
396:
386:
380:
374:
368:
362:
342:
322:
302:
282:
257:
241:
191:
147:
140:
121:
114:
17:
12:
11:
5:
3828:
3826:
3818:
3817:
3812:
3807:
3797:
3796:
3792:
3791:
3768:
3767:
3764:
3763:
3762:
3761:
3758:
3747:
3741:
3735:
3734:
3731:
3730:
3727:
3726:
3724:
3723:
3718:
3716:Duvortuxizumab
3713:
3707:
3705:
3701:
3700:
3698:
3697:
3692:
3686:
3684:
3678:
3677:
3675:
3674:
3669:
3664:
3659:
3654:
3649:
3635:
3630:
3625:
3620:
3615:
3610:
3605:
3600:
3595:
3590:
3585:
3580:
3575:
3570:
3565:
3560:
3555:
3550:
3545:
3540:
3535:
3530:
3525:
3520:
3515:
3510:
3505:
3500:
3495:
3490:
3485:
3480:
3475:
3470:
3465:
3460:
3455:
3450:
3445:
3440:
3435:
3430:
3425:
3420:
3415:
3410:
3405:
3400:
3395:
3390:
3385:
3383:Brontictuzumab
3380:
3375:
3370:
3365:
3360:
3355:
3349:
3347:
3341:
3340:
3338:
3337:
3332:
3327:
3322:
3317:
3312:
3307:
3302:
3297:
3292:
3287:
3282:
3277:
3272:
3267:
3262:
3257:
3252:
3247:
3242:
3236:
3234:
3228:
3227:
3225:
3224:
3219:
3214:
3209:
3204:
3199:
3194:
3189:
3184:
3179:
3174:
3169:
3164:
3159:
3154:
3149:
3144:
3139:
3134:
3129:
3124:
3119:
3114:
3109:
3104:
3099:
3094:
3088:
3086:
3082:
3081:
3079:
3078:
3073:
3068:
3063:
3058:
3053:
3048:
3043:
3038:
3033:
3028:
3023:
3018:
3013:
3008:
3003:
2998:
2993:
2988:
2983:
2978:
2973:
2968:
2963:
2958:
2953:
2948:
2943:
2938:
2933:
2928:
2923:
2918:
2913:
2908:
2903:
2898:
2893:
2888:
2883:
2878:
2873:
2868:
2863:
2858:
2853:
2850:+hyaluronidase
2843:
2838:
2833:
2827:
2825:
2818:
2812:
2811:
2805:
2803:
2802:
2795:
2788:
2780:
2771:
2770:
2768:
2767:
2762:
2757:
2752:
2747:
2742:
2737:
2732:
2727:
2722:
2717:
2712:
2707:
2702:
2697:
2692:
2687:
2682:
2677:
2672:
2667:
2662:
2657:
2652:
2651:
2650:
2645:
2640:
2635:
2630:
2620:
2619:
2618:
2613:
2600:
2599:
2598:
2593:
2588:
2583:
2578:
2570:CDK inhibitors
2566:
2565:
2564:
2559:
2554:
2541:
2540:
2539:
2534:
2529:
2517:
2501:
2481:
2469:fusion protein
2464:
2462:
2458:
2457:
2454:
2453:
2451:
2450:
2449:
2448:
2443:
2438:
2433:
2428:
2415:
2414:
2413:
2412:
2407:
2402:
2385:
2384:
2383:
2382:
2377:
2372:
2367:
2354:
2353:
2352:
2351:
2346:
2341:
2336:
2331:
2326:
2321:
2308:
2307:
2301:
2289:
2288:
2287:
2286:
2281:
2276:
2271:
2266:
2261:
2256:
2243:
2241:
2235:
2234:
2232:
2231:
2210:
2209:
2208:(VEGFR, EGFR).
2164:
2163:
2162:
2161:
2156:
2151:
2138:
2137:
2136:
2135:
2130:
2125:
2120:
2115:
2110:
2105:
2100:
2095:
2090:
2085:
2080:
2075:
2062:
2061:
2045:
2039:
2034:
2029:
2024:
2019:
2014:
2009:
1989:
1988:
1987:
1986:
1981:
1976:
1966:HER1/EGFR and
1962:
1961:
1955:
1950:
1945:
1940:
1935:
1930:
1925:
1920:
1915:
1910:
1905:
1900:
1884:
1882:
1873:
1866:
1865:
1862:
1861:
1859:
1858:
1853:
1848:
1843:
1838:
1833:
1828:
1823:
1818:
1813:
1808:
1803:
1798:
1793:
1788:
1783:
1778:
1773:
1768:
1763:
1758:
1753:
1748:
1743:
1738:
1733:
1728:
1723:
1718:
1713:
1708:
1703:
1698:
1693:
1688:
1683:
1678:
1673:
1668:
1663:
1658:
1653:
1648:
1645:+hyaluronidase
1638:
1632:
1630:
1626:
1625:
1623:
1622:
1605:
1604:
1578:
1573:
1568:
1563:
1558:
1553:
1519:
1517:
1507:
1506:
1504:
1503:
1491:
1485:
1473:
1471:
1467:
1466:
1464:
1463:
1457:
1452:
1449:+hyaluronidase
1432:
1426:
1410:
1408:
1399:
1389:
1388:
1374:
1372:
1371:
1364:
1357:
1349:
1341:
1340:
1308:
1278:
1257:(3): 320–327.
1237:
1186:
1139:
1095:
1046:
1016:
986:
956:
897:
864:
814:
784:
751:
719:
687:
657:
628:
597:
596:
594:
591:
582:
579:
573:(CHMP) of the
566:
563:
561:
558:
556:designations.
537:
534:
528:
525:
508:
505:
496:
493:
405:
404:
394:
388:
387:
384:
378:
372:
366:
360:
355:
349:
348:
344:
343:
341:
340:
332:
330:
324:
323:
321:
320:
312:
310:
304:
303:
301:
300:
292:
290:
284:
283:
281:
280:
272:
270:
264:
263:
259:
258:
256:
255:
246:
231:
220:
206:
204:
198:
197:
193:
192:
190:
189:
176:
174:
168:
167:
165:Antineoplastic
162:
156:
155:
150:
148:administration
142:
141:
139:
138:
136:
126:
124:
116:
115:
113:
112:
94:
92:
86:
85:
82:
78:
77:
73:
72:
63:
57:
56:
51:
45:
44:
39:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
3827:
3816:
3813:
3811:
3808:
3806:
3803:
3802:
3800:
3790:
3780:
3776:
3759:
3757:
3754:
3753:
3751:
3748:
3745:
3742:
3740:
3737:
3736:
3732:
3722:
3719:
3717:
3714:
3712:
3709:
3708:
3706:
3702:
3696:
3693:
3691:
3688:
3687:
3685:
3683:
3679:
3673:
3670:
3668:
3665:
3663:
3660:
3658:
3655:
3653:
3650:
3647:
3643:
3639:
3636:
3634:
3631:
3629:
3626:
3624:
3621:
3619:
3616:
3614:
3611:
3609:
3606:
3604:
3601:
3599:
3598:Rosmantuzumab
3596:
3594:
3591:
3589:
3586:
3584:
3581:
3579:
3576:
3574:
3571:
3569:
3566:
3564:
3561:
3559:
3556:
3554:
3551:
3549:
3546:
3544:
3541:
3539:
3536:
3534:
3531:
3529:
3526:
3524:
3521:
3519:
3516:
3514:
3511:
3509:
3506:
3504:
3501:
3499:
3496:
3494:
3491:
3489:
3486:
3484:
3481:
3479:
3476:
3474:
3471:
3469:
3466:
3464:
3461:
3459:
3456:
3454:
3453:Enoblituzumab
3451:
3449:
3446:
3444:
3441:
3439:
3436:
3434:
3431:
3429:
3426:
3424:
3421:
3419:
3416:
3414:
3411:
3409:
3406:
3404:
3401:
3399:
3396:
3394:
3391:
3389:
3386:
3384:
3381:
3379:
3376:
3374:
3371:
3369:
3366:
3364:
3361:
3359:
3356:
3354:
3351:
3350:
3348:
3346:
3342:
3336:
3333:
3331:
3328:
3326:
3323:
3321:
3318:
3316:
3313:
3311:
3308:
3306:
3303:
3301:
3298:
3296:
3293:
3291:
3288:
3286:
3283:
3281:
3278:
3276:
3273:
3271:
3268:
3266:
3263:
3261:
3258:
3256:
3253:
3251:
3248:
3246:
3243:
3241:
3238:
3237:
3235:
3233:
3229:
3223:
3220:
3218:
3215:
3213:
3210:
3208:
3205:
3203:
3200:
3198:
3195:
3193:
3190:
3188:
3185:
3183:
3180:
3178:
3175:
3173:
3170:
3168:
3165:
3163:
3160:
3158:
3155:
3153:
3150:
3148:
3145:
3143:
3140:
3138:
3135:
3133:
3130:
3128:
3125:
3123:
3120:
3118:
3115:
3113:
3110:
3108:
3105:
3103:
3100:
3098:
3095:
3093:
3090:
3089:
3087:
3083:
3077:
3074:
3072:
3069:
3067:
3064:
3062:
3059:
3057:
3054:
3052:
3049:
3047:
3044:
3042:
3039:
3037:
3034:
3032:
3029:
3027:
3024:
3022:
3019:
3017:
3014:
3012:
3009:
3007:
3006:Pembrolizumab
3004:
3002:
2999:
2997:
2994:
2992:
2989:
2987:
2984:
2982:
2979:
2977:
2974:
2972:
2969:
2967:
2964:
2962:
2959:
2957:
2954:
2952:
2949:
2947:
2944:
2942:
2939:
2937:
2934:
2932:
2929:
2927:
2924:
2922:
2919:
2917:
2914:
2912:
2909:
2907:
2904:
2902:
2899:
2897:
2894:
2892:
2889:
2887:
2884:
2882:
2879:
2877:
2874:
2872:
2869:
2867:
2864:
2862:
2859:
2857:
2854:
2851:
2847:
2844:
2842:
2841:Ascrinvacumab
2839:
2837:
2834:
2832:
2829:
2828:
2826:
2822:
2819:
2817:
2813:
2808:
2801:
2796:
2794:
2789:
2787:
2782:
2781:
2778:
2766:
2763:
2761:
2758:
2756:
2753:
2751:
2748:
2746:
2743:
2741:
2738:
2736:
2733:
2731:
2728:
2726:
2723:
2721:
2718:
2716:
2713:
2711:
2708:
2706:
2703:
2701:
2698:
2696:
2693:
2691:
2688:
2686:
2683:
2681:
2680:Larotrectinib
2678:
2676:
2673:
2671:
2668:
2666:
2663:
2661:
2658:
2656:
2653:
2649:
2646:
2644:
2641:
2639:
2636:
2634:
2631:
2629:
2626:
2625:
2624:
2621:
2617:
2614:
2612:
2609:
2608:
2607:
2605:
2601:
2597:
2594:
2592:
2589:
2587:
2584:
2582:
2579:
2577:
2574:
2573:
2572:
2571:
2567:
2563:
2560:
2558:
2555:
2553:
2550:
2549:
2548:
2546:
2542:
2538:
2535:
2533:
2532:Ridaforolimus
2530:
2528:
2525:
2524:
2523:
2522:
2518:
2515:
2511:
2510:
2506:
2502:
2499:
2495:
2494:
2490:
2486:
2482:
2479:
2475:
2474:
2470:
2466:
2465:
2463:
2459:
2447:
2444:
2442:
2441:Pirtobrutinib
2439:
2437:
2436:Orelabrutinib
2434:
2432:
2429:
2427:
2426:Acalabrutinib
2424:
2423:
2422:
2421:
2417:
2416:
2411:
2408:
2406:
2403:
2401:
2398:
2397:
2396:
2395:
2391:
2387:
2386:
2381:
2378:
2376:
2373:
2371:
2368:
2366:
2363:
2362:
2361:
2360:
2356:
2355:
2350:
2347:
2345:
2342:
2340:
2337:
2335:
2332:
2330:
2327:
2325:
2322:
2320:
2317:
2316:
2315:
2314:
2310:
2309:
2305:
2302:
2300:
2296:
2295:
2291:
2290:
2285:
2282:
2280:
2277:
2275:
2272:
2270:
2267:
2265:
2262:
2260:
2257:
2255:
2252:
2251:
2250:
2249:
2245:
2244:
2242:
2240:
2236:
2229:
2225:
2221:
2218:
2216:
2212:
2211:
2207:
2203:
2202:Selpercatinib
2199:
2198:Repotrectinib
2195:
2191:
2187:
2186:Larotrectinib
2183:
2179:
2175:
2172:
2170:
2166:
2165:
2160:
2157:
2155:
2152:
2150:
2147:
2146:
2145:
2144:
2140:
2139:
2134:
2131:
2129:
2126:
2124:
2121:
2119:
2116:
2114:
2111:
2109:
2106:
2104:
2101:
2099:
2096:
2094:
2091:
2089:
2086:
2084:
2081:
2079:
2076:
2074:
2071:
2070:
2069:
2068:
2064:
2063:
2059:
2055:
2051:
2050:
2046:
2043:
2040:
2038:
2035:
2033:
2030:
2028:
2025:
2023:
2020:
2018:
2015:
2013:
2010:
2008:
2004:
2003:
1999:
1994:
1993:RTK class III
1991:
1990:
1985:
1982:
1980:
1977:
1975:
1972:
1971:
1970:
1969:
1964:
1963:
1959:
1956:
1954:
1951:
1949:
1946:
1944:
1941:
1939:
1936:
1934:
1931:
1929:
1926:
1924:
1921:
1919:
1916:
1914:
1911:
1909:
1906:
1904:
1901:
1899:
1895:
1894:
1889:
1886:
1885:
1883:
1881:
1877:
1874:
1871:
1867:
1857:
1854:
1852:
1849:
1847:
1844:
1842:
1839:
1837:
1834:
1832:
1829:
1827:
1824:
1822:
1819:
1817:
1814:
1812:
1809:
1807:
1804:
1802:
1799:
1797:
1794:
1792:
1789:
1787:
1784:
1782:
1779:
1777:
1776:Pembrolizumab
1774:
1772:
1769:
1767:
1764:
1762:
1759:
1757:
1754:
1752:
1749:
1747:
1744:
1742:
1741:Mogamulizumab
1739:
1737:
1734:
1732:
1729:
1727:
1724:
1722:
1719:
1717:
1714:
1712:
1709:
1707:
1704:
1702:
1699:
1697:
1694:
1692:
1689:
1687:
1684:
1682:
1679:
1677:
1674:
1672:
1669:
1667:
1664:
1662:
1659:
1657:
1654:
1652:
1649:
1646:
1642:
1639:
1637:
1634:
1633:
1631:
1627:
1620:
1616:
1615:
1610:
1607:
1606:
1602:
1598:
1597:
1592:
1588:
1587:
1582:
1579:
1577:
1574:
1572:
1569:
1567:
1564:
1562:
1561:Mosunetuzumab
1559:
1557:
1554:
1552:
1548:
1547:
1542:
1541:Mosunetuzumab
1538:
1534:
1530:
1529:
1524:
1521:
1520:
1518:
1516:
1512:
1508:
1501:
1497:
1496:
1492:
1489:
1486:
1484:
1480:
1479:
1475:
1474:
1472:
1468:
1461:
1458:
1456:
1453:
1450:
1446:
1442:
1438:
1437:
1433:
1430:
1427:
1425:
1421:
1420:
1415:
1412:
1411:
1409:
1407:
1403:
1400:
1397:
1394:
1390:
1385:
1381:
1377:
1370:
1365:
1363:
1358:
1356:
1351:
1350:
1347:
1335:
1330:
1326:
1322:
1318:
1312:
1309:
1296:
1292:
1288:
1282:
1279:
1274:
1270:
1265:
1260:
1256:
1252:
1248:
1241:
1238:
1233:
1229:
1224:
1219:
1214:
1209:
1205:
1201:
1197:
1190:
1187:
1183:
1182:public domain
1164:
1160:
1158:
1149:
1143:
1140:
1136:
1135:public domain
1117:
1113:
1111:
1105:
1099:
1096:
1091:
1087:
1082:
1077:
1073:
1069:
1065:
1061:
1057:
1050:
1047:
1034:
1030:
1026:
1020:
1017:
1004:
1000:
996:
990:
987:
974:
970:
966:
960:
957:
953:
952:public domain
934:
930:
926:
920:
918:
916:
914:
912:
910:
908:
906:
904:
902:
898:
885:
881:
877:
871:
869:
865:
851:
847:
843:
837:
835:
833:
831:
829:
827:
825:
823:
821:
819:
815:
802:
798:
794:
788:
785:
772:
768:
764:
758:
756:
752:
739:
735:
734:
733:Health Canada
729:
723:
720:
707:
703:
702:
701:Health Canada
697:
691:
688:
675:
671:
667:
661:
658:
646:
642:
638:
632:
629:
616:
612:
608:
602:
599:
592:
590:
588:
580:
578:
576:
572:
564:
559:
557:
555:
551:
547:
542:
535:
533:
526:
524:
522:
521:neurotoxicity
518:
514:
513:boxed warning
506:
504:
502:
494:
492:
490:
486:
480:
478:
474:
470:
466:
462:
458:
454:
450:
445:
443:
439:
435:
431:
427:
423:
419:
416:, is a human
415:
411:
395:
393:
389:
356:
354:
350:
345:
338:
334:
333:
331:
329:
325:
318:
314:
313:
311:
309:
305:
298:
294:
293:
291:
289:
285:
278:
274:
273:
271:
269:
265:
260:
254: Rx-only
247:
244:
232:
230:
221:
218:
208:
207:
205:
203:
199:
194:
186:
181:
178:
177:
175:
173:
169:
166:
163:
161:
157:
154:
151:
149:
143:
137:
128:
127:
125:
123:
117:
110:
105:
96:
95:
93:
91:
87:
83:
79:
76:Clinical data
74:
71:
67:
64:
62:
58:
55:
52:
50:
46:
43:
40:
38:
34:
31:
27:
19:
3815:Orphan drugs
3613:Sibrotuzumab
3578:Parsatuzumab
3563:Otlertuzumab
3558:Odronextamab
3553:Ocaratuzumab
3548:Obinutuzumab
3523:Lumretuzumab
3478:Flotetuzumab
3473:Ficlatuzumab
3468:Farletuzumab
3463:Etaracizumab
3448:Emibetuzumab
3335:Zolbetuximab
3310:Margetuximab
3290:Girentuximab
3152:Minretumomab
3117:Blinatumomab
3056:Teprotumumab
3036:Seribantumab
2861:Botensilimab
2846:Atezolizumab
2831:Adecatumumab
2720:Pexidartinib
2705:Odronextamab
2675:Gilteritinib
2655:Cabozantinib
2602:
2568:
2543:
2537:Temsirolimus
2519:
2503:
2485:proapoptotic
2483:
2467:
2446:Zanubrutinib
2418:
2388:
2357:
2334:Lestaurtinib
2313:Janus kinase
2311:
2292:
2246:
2239:Non-receptor
2220:Cabozantinib
2213:
2182:Infigratinib
2167:
2141:
2083:Fruquintinib
2065:
2058:Gilteritinib
2054:Lestaurtinib
2047:
1996:
1965:
1938:Mobocertinib
1903:Aumolertinib
1891:
1856:Tremelimumab
1841:Tislelizumab
1835:
1796:Retifanlimab
1671:Blinatumomab
1641:Atezolizumab
1612:
1594:
1584:
1566:Obinutuzumab
1544:
1526:
1493:
1476:
1434:
1417:
1334:10665/330879
1324:
1320:
1311:
1299:. Retrieved
1290:
1281:
1254:
1250:
1240:
1203:
1199:
1189:
1167:. Retrieved
1154:
1142:
1120:. Retrieved
1107:
1098:
1063:
1059:
1049:
1037:. Retrieved
1028:
1019:
1007:. Retrieved
989:
977:. Retrieved
968:
959:
937:. Retrieved
888:. Retrieved
879:
854:. Retrieved
845:
805:. Retrieved
787:
775:. Retrieved
766:
742:. Retrieved
731:
722:
710:. Retrieved
699:
690:
680:10 September
678:. Retrieved
669:
660:
648:. Retrieved
640:
631:
621:10 September
619:. Retrieved
610:
601:
584:
568:
565:Legal status
543:
539:
530:
510:
498:
495:Medical uses
481:
446:
413:
409:
408:
277:2119595-80-9
202:Legal status
196:Legal status
90:License data
18:
3746:from market
3721:Ontuxizumab
3695:Ertumaxomab
3690:Catumaxomab
3662:Vanucizumab
3642:+deruxtecan
3638:Trastuzumab
3633:Tigatuzumab
3568:Onartuzumab
3543:Nimotuzumab
3533:Milatuzumab
3503:Labetuzumab
3493:Imgatuzumab
3458:Epcoritamab
3443:Emactuzumab
3428:Dalotuzumab
3418:Dacetuzumab
3398:Cirmtuzumab
3373:Bevacizumab
3358:Alemtuzumab
3330:Ublituximab
3280:Ensituximab
3275:Ecromeximab
3270:Dinutuximab
3255:Carotuximab
3245:Bavituximab
3222:Tositumomab
3217:Tenatumomab
3187:Racotumomab
3132:Edrecolomab
3107:Arcitumomab
3076:Zalutumumab
3066:Vantictumab
3041:Sugemalimab
3031:Robatumumab
3026:Rilotumumab
3021:Ramucirumab
2996:Panitumumab
2971:Necitumumab
2961:Mapatumumab
2956:Lucatumumab
2951:Lexatumumab
2941:Istiratumab
2926:Intetumumab
2911:Flanvotumab
2906:Figitumumab
2891:Dusigitumab
2886:Duligotumab
2876:Daratumumab
2871:Conatumumab
2866:Cixutumumab
2856:Balstilimab
2836:Amivantamab
2750:Tebentafusp
2730:Regorafenib
2725:Quizartinib
2715:Pemigatinib
2695:Midostaurin
2670:Erdafitinib
2665:Entrectinib
2648:Parsaclisib
2596:Trilaciclib
2586:Palbociclib
2581:Dalpiciclib
2576:Abemaciclib
2478:Aflibercept
2405:Entrectinib
2375:Selumetinib
2370:Cobimetinib
2365:Binimetinib
2349:Ruxolitinib
2339:Momelotinib
2319:Baricitinib
2217:inhibitors:
2194:Pralsetinib
2190:Pemigatinib
2178:Futibatinib
2174:Entrectinib
2171:inhibitors:
2103:Regorafenib
2007:Avapritinib
1953:Rociletinib
1948:Osimertinib
1913:Dacomitinib
1851:Toripalimab
1836:Teclistamab
1826:Talquetamab
1821:Tafasitamab
1816:Sugemalimab
1811:Serplulimab
1801:Sabatolimab
1791:Ramucirumab
1786:Prolgolimab
1756:Necitumumab
1711:Epcoritamab
1691:Dostarlimab
1681:Daratumumab
1636:Amivantamab
1601:Alemtuzumab
1591:Brentuximab
1581:Tositumomab
1556:Ibritumomab
1537:Elranatamab
1500:Bevacizumab
1488:Edrecolomab
1483:Catumaxomab
1445:Trastuzumab
1429:Panitumumab
1206:: 741–751.
777:18 November
546:orphan drug
469:lymphopenia
453:neutropenia
410:Teclistamab
403: g·mol
262:Identifiers
109:Teclistamab
81:Other names
23:Teclistamab
3799:Categories
3667:Veltuzumab
3646:+emtansine
3618:Simtuzumab
3583:Pertuzumab
3513:Lintuzumab
3488:Glofitamab
3438:Elotuzumab
3423:Demcizumab
3363:Axatilimab
3353:Abituzumab
3325:Siltuximab
3300:Isatuximab
3240:Amatuximab
3212:Pintumomab
3182:Pemtumomab
3177:Oregovomab
3112:Bectumomab
3092:Abagovomab
3046:Tarextumab
3016:Radretumab
3011:Pritumumab
3001:Patritumab
2991:Olaratumab
2986:Ofatumumab
2976:Nesvacumab
2966:Narnatumab
2936:Iratumumab
2931:Ipilimumab
2901:Enoticumab
2881:Drozitumab
2809:for tumors
2765:Venetoclax
2760:Vandetanib
2735:Ripretinib
2700:Nintedanib
2685:Lenvatinib
2660:Capmatinib
2643:Idelalisib
2633:Copanlisib
2606:inhibitors
2591:Ribociclib
2562:Vismodegib
2547:inhibitors
2527:Everolimus
2493:prohibitin
2410:Lorlatinib
2400:Crizotinib
2380:Trametinib
2344:Pacritinib
2329:Filgotinib
2324:Fedratinib
2228:Crizotinib
2224:Capmatinib
2206:Vandetanib
2154:Brigatinib
2133:Vandetanib
2093:Nintedanib
2088:Lenvatinib
2027:Ripretinib
1958:Vandetanib
1933:Lazertinib
1908:Brigatinib
1831:Tarlatamab
1766:Olaratumab
1726:Isatuximab
1721:Ipilimumab
1701:Elotuzumab
1696:Durvalumab
1676:Cemiplimab
1666:Bermekimab
1656:Axatilimab
1571:Ofatumumab
1551:Glofitamab
1533:Glofitamab
1441:Pertuzumab
1169:14 January
1122:22 January
1039:26 October
1009:27 October
979:26 October
939:28 October
856:14 October
807:4 December
650:22 October
607:"Tecvayli"
593:References
392:Molar mass
317:54534MX6Z9
268:CAS Number
160:Drug class
3756:Phase III
3744:Withdrawn
3538:Naxitamab
3528:Matuzumab
3345:Humanized
3320:Rituximab
3285:Futuximab
3260:Cetuximab
3197:Solitomab
3157:Mitumomab
3147:Lilotomab
3127:Detumomab
3071:Votumumab
3061:Tovetumab
2981:Nivolumab
2946:Icrucumab
2916:Ganitumab
2755:Tepotinib
2745:Sunitinib
2740:Sorafenib
2710:Pazopanib
2690:Masitinib
2638:Duvelisib
2628:Alpelisib
2616:Sotorasib
2611:Adagrasib
2557:Sonidegib
2552:Glasdegib
2498:Adipotide
2431:Ibrutinib
2304:Dasatinib
2299:Bosutinib
2284:Radotinib
2279:Ponatinib
2274:Nilotinib
2264:Dasatinib
2259:Bosutinib
2254:Asciminib
2222:(VEGFR),
2180:(FGFR2),
2159:Ceritinib
2149:Alectinib
2128:Toceranib
2123:Tivozanib
2118:Sunitinib
2113:Sorafenib
2108:Semaxanib
2098:Pazopanib
2078:Cediranib
2042:Toceranib
2037:Sunitinib
2032:Sorafenib
2022:Pazopanib
2017:Masitinib
1984:Tucatinib
1979:Neratinib
1974:Lapatinib
1943:Olmutinib
1923:Gefitinib
1918:Erlotinib
1893:HER1/EGFR
1761:Nivolumab
1751:Naxitamab
1576:Rituximab
1424:Cetuximab
1419:HER1/EGFR
744:3 January
501:indicated
477:pneumonia
442:malignant
146:Routes of
120:Pregnancy
54:Humanized
3789:Medicine
3232:Chimeric
3142:Igovomab
2545:hedgehog
2507:against
2505:exotoxin
2471:against
2420:Bruton's
2269:Imatinib
2192:(FGFR),
2188:(NTRK),
2073:Axitinib
2012:Axitinib
1968:HER2/neu
1928:Icotinib
1898:Afatinib
1872:("-nib")
1651:Avelumab
1523:lymphoid
1515:lymphoma
1511:Leukemia
1436:HER2/neu
1398:("-mab")
1295:Archived
1273:37848191
1232:37497430
1223:10368105
1163:Archived
1116:Archived
1090:36352205
1033:Archived
1003:Archived
973:Archived
933:Archived
884:Archived
850:Archived
801:Archived
771:Archived
767:DailyMed
738:Archived
706:Archived
674:Archived
615:Archived
473:diarrhea
414:Tecvayli
288:DrugBank
172:ATC code
122:category
104:DailyMed
2248:bcr-abl
1609:myeloid
1301:3 March
1081:9646474
1001:(FDA).
997:. U.S.
927:. U.S.
890:30 July
880:Janssen
795:. U.S.
712:3 March
536:History
430:T-cells
353:Formula
297:DB16655
245:Rx-only
242:WARNING
227::
188:)
182: (
180:L01FX24
135: C
106::
3775:Portal
3739:WHO-EM
1495:VEGF-A
1271:
1230:
1220:
1088:
1078:
552:, and
457:anemia
434:B-cell
337:D12177
239:
229:℞-only
215:
102:
61:Target
49:Source
3085:Mouse
2824:Human
2816:Tumor
2489:ANXA2
2461:Other
2359:MAP2K
2230:(ALK)
2215:c-MET
2067:VEGFR
2002:PDGFR
1998:C-kit
1629:Other
1478:EpCAM
1327:(3).
1159:(FDA)
1155:U.S.
1151:(PDF)
1112:(FDA)
1108:U.S.
1060:Drugs
581:Names
2604:KRAS
2509:IL-2
2491:and
2473:VEGF
2390:EML4
2049:FLT3
2000:and
1888:ErbB
1614:CD33
1596:CD52
1586:CD30
1546:CD20
1414:ErbB
1303:2023
1269:PMID
1228:PMID
1171:2024
1124:2023
1086:PMID
1041:2022
1011:2022
981:2022
941:2022
892:2022
858:2022
809:2022
779:2022
746:2024
714:2024
682:2023
652:2023
623:2023
438:BCMA
432:and
379:2003
373:1695
367:9847
361:6383
328:KEGG
308:UNII
66:BCMA
37:Type
2394:ALK
2294:Src
2169:RET
2143:ALK
1593:),
1583:),
1543:),
1528:CD3
1384:L01
1329:hdl
1259:doi
1255:112
1218:PMC
1208:doi
1076:PMC
1068:doi
645:FDA
426:CD3
401:.25
399:662
397:143
185:WHO
70:CD3
3801::
3752::
3644:/
2226:,
2196:,
2184:,
2056:,
1995::
1890::
1611::
1539:,
1535:,
1525::
1443:,
1416::
1393:CI
1378:/
1325:33
1323:.
1289:.
1267:.
1253:.
1249:.
1226:.
1216:.
1204:15
1202:.
1198:.
1153:.
1106:.
1084:.
1074:.
1064:82
1062:.
1058:.
1027:.
967:.
900:^
878:.
867:^
844:.
817:^
765:.
754:^
730:.
698:.
668:.
643:.
639:.
609:.
548:,
491:.
475:,
385:40
250:EU
235:US
224:CA
217:S4
211:AU
131:AU
99:US
68:,
3777::
3648:)
3640:(
2852:)
2848:(
2799:e
2792:t
2785:v
2516:)
2512:(
2500:)
2496:(
2480:)
2476:(
2392:-
2306:)
2297:(
2052:(
2044:)
2005:(
1960:)
1896:(
1647:)
1643:(
1621:)
1617:(
1603:)
1599:(
1589:(
1549:(
1531:(
1513:/
1502:)
1498:(
1490:)
1481:(
1462:)
1451:)
1447:(
1439:(
1431:)
1422:(
1386:)
1382:(
1368:e
1361:t
1354:v
1337:.
1331::
1305:.
1275:.
1261::
1234:.
1210::
1184:.
1173:.
1137:.
1126:.
1092:.
1070::
1043:.
1013:.
983:.
954:.
943:.
894:.
860:.
811:.
781:.
748:.
716:.
684:.
654:.
625:.
382:S
376:O
370:N
364:H
358:C
252::
237::
213::
133::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.